This study explored the in vivo effects and mechanisms of the modern classical prescription Supplemented Gegen Qinlian Decoction Tang against diabetic kidney disease. Sixty rats were randomly divided into the normal group, model group, Gegen Qinlian Decoction Tang group, and rosiglitazone(ROS) group.
The modified diabetic kidney disease rat model was established by employing the following three methods: exposure to high-fat diet, unilateral nephrectomy, and intraperitoneal injection of streptozotocin(STZ). After modeling, rats in the four groups were treated with double distilled water, Gegen Qinlian Decoction Tang suspension, and ROS suspension, respectively, by gavage every day.
At the end of the 6 th week of drug administration, all the rats were sacrificed for collecting urine, blood, and kidney tissue, followed by the examination of rat general conditions, urine and blood biochemical indicators, glomerulosclerosis-related indicators, podocyte pyroptosis markers, insulin resistance(IR)-related indicators, and key molecules in the insulin receptor substrate(IRS) 1/phosphatidylinositol-3-kinase(PI3 K)/serine threonine kinase(Akt) signaling pathway.
The results showed that Gegen Qinlian Decoction Tang and ROS improved the general conditions, some renal function indicators and glomerulosclerosis of diabetic kidney disease model rats without affecting the blood glucose(BG). Besides, they ameliorated the expression characteristics and levels of podocyte pyroptosis markers, alleviated IR, and up-regulated the protein expression levels of the key molecules in IRS1/PI3 K/Akt pathway to varying degrees.
In conclusion, similar to ROS, Gegen Qinlian Decoction Tang relieves diabetic kidney disease by targeting multiple targets in vivo. Specifically, it exerts the therapeutic effects by alleviating podocyte pyroptosis and IR. This study has preliminarily provided the pharmacological evidence for the research and development of new drugs for the treatment of diabetic kidney disease based on Gegen Qinlian Decoction Tang.